hapabapa
- Dyne Therapeutics (NASDAQ:DYN) introduced Tuesday that the U.S. Meals and Drug Administration (FDA) issued fast-track designation for DYNE-101, an experimental remedy for a uncommon muscle dysfunction referred to as myotonic dystrophy kind 1 (DM1).
- DYNE-101, a drug with orphan drug designations within the
